Telix (ASX:TLX) Green Light to Move Into the Pivotal Phase 3 Study

TLX591-Tx Hits Safety Goals, US Enrollment Now in Sight

Telix is developing a new type of cancer treatment for advanced prostate cancer called TLX591-Tx.

Rather than relying on traditional chemotherapy or standard radiation, this therapy is designed to deliver a radioactive payload directly to prostate cancer cells using an antibody that targets PSMA, a protein that is highly overexpressed in prostate cancer.

The easiest way to think about it is as a guided missile for cancer cells.

That is why today’s announcement mattered so much. The update helped drive a 9% spike in the share price and confirmed that Phase 3 Part 1 of the study successfully met all primary objectives.

For us, that is the key takeaway.

This result gives Telix the green light to start moving into the larger and far more important Phase 3 Part 2 study. That next stage is what will determine whether the drug can improve patient outcomes strongly enough to support regulatory approval.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

Strong Safety and Targeting Data

This is important for investors because Part 1 was a prerequisite for the program to continue. Before the FDA would allow the pivotal Part 2 study to proceed in the US, Telix needed to show clean early safety and dose data. Now, with that data in hand, the company can submit an IND amendment to the FDA to unlock US patient enrolment, which matters because the US is the world’s largest prostate cancer market.

And for anyone in biotech, the next question is obvious. What actually makes TLX591-Tx different? What Telix demonstrated over the 15-day timeline is that the antibody stays at the tumour site for longer, allowing patients to receive a more sustained radiation dose directly to the cancer. That matters because a therapy that remains bound to the tumour for longer can potentially be more effective than one that washes out too quickly.

Another important point is flexibility. TLX591-Tx was used alongside abiraterone, enzalutamide, and docetaxel without altering how the drug behaved in the body. That gives clinicians more freedom to use it with existing standard-of-care treatments without creating dosing complications.

There is also a practical advantage in the treatment regimen itself. TLX591-Tx is given in two doses, 14 days apart. That compares favourably with alternatives that may require six infusions over 36 weeks. A simpler dosing schedule can improve patient compliance and make treatment more manageable in the real world.

Early Data Looks Clean

The study also confirmed something else that is critical. It looked at how much radiation was being absorbed by tumours versus healthy tissue. For this type of therapy to work well, you want a high dose reaching the tumour site while limiting unnecessary exposure elsewhere. And that is exactly where Telix produced encouraging data. The company demonstrated meaningful absorbed doses across 132 tumour lesions, including bone metastases, lymph node metastases, and soft tissue lesions. That confirms the antibody is successfully targeting and binding to PSMA-positive tumours throughout the body, which is a key part of the investment thesis.

TLX591-Tx Moves Closer to the US Market

There is still a while to go for Telix.

Part 1 was just a small test group of 36 people, and there is still no efficacy data showing that patients are actually living longer.

So while today’s announcement is a meaningful positive step in Telix’s clinical development program, it is important to frame it correctly.

Part 1 was always expected to succeed.

Its purpose was to establish safety parameters before the pivotal efficacy study, not to prove that the drug works.

What it does do is remove a key gatekeeping risk.

The safety profile is now better characterised, the dosimetry has been confirmed, and there is no reason at this stage to believe TLX591-Tx cannot be combined with existing standard-of-care drugs.